Ascendis Pharma Profit Margin 2015-2021 | ASND
Current and historical gross margin, operating margin and net profit margin for Ascendis Pharma (ASND) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Ascendis Pharma net profit margin as of June 30, 2021 is -9108.77%.
|Ascendis Pharma Annual Profit Margins
|Ascendis Pharma Quarterly Profit Margins
||Medical - Biomedical and Genetics
Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark.